ZURA BIO LIMITED General and Administrative Expense
ZURA BIO LIMITED (ZURA) reported General and Administrative Expense of $8.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-11
- ZURA BIO LIMITED general and administrative expense for the quarter ending 2026-06-30 was $8.62M, a 7.94% decline year-over-year.
- ZURA BIO LIMITED general and administrative expense for the quarter ending 2026-03-31 was $10.75M, a 22.47% increase year-over-year.
- ZURA BIO LIMITED general and administrative expense for the quarter ending 2025-12-31 was $7.46M, a 14.83% increase year-over-year.
- ZURA BIO LIMITED general and administrative expense for the quarter ending 2025-09-30 was $7.57M, a 43.03% decline year-over-year.
- ZURA BIO LIMITED general and administrative expense for fiscal 2025 was $33.16M, a 7.72% increase from fiscal 2024.
- ZURA BIO LIMITED general and administrative expense for fiscal 2024 was $30.79M, a 65.18% increase from fiscal 2023.
- ZURA BIO LIMITED general and administrative expense for fiscal 2023 was $18.64M, a 712.50% increase from fiscal 2022.
- ZURA BIO LIMITED general and administrative expense for fiscal 2022 was $2.29M.
| Period end | General and Administrative Expense 1 month | General and Administrative Expense 2 month | General and Administrative Expense 3 month | General and Administrative Expense 3 month as first filed | General and Administrative Expense 4 month | General and Administrative Expense 5 month | General and Administrative Expense 6 month | General and Administrative Expense 7 month | General and Administrative Expense 8 month | General and Administrative Expense 9 month | General and Administrative Expense 10 month | General and Administrative Expense 11 month | General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.62M 10-Q · filed 2026-08-11 | $19.37M 10-Q · filed 2026-08-11 | $26.82M derived: sum of 3 quarters · filed 2026-08-11 | $34.39M derived: sum of 4 quarters · filed 2026-08-11 | |||||||||
| 2026-03-31 | $10.75M 10-Q · filed 2026-05-07 | $18.21M derived: sum of 2 quarters · filed 2026-05-07 | $25.78M derived: sum of 3 quarters · filed 2026-05-07 | $35.14M derived: sum of 4 quarters · filed 2026-08-11 | |||||||||
| 2025-12-31 | $7.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $15.03M derived: sum of 2 quarters · filed 2026-03-19 | $24.38M derived: sum of 3 quarters · filed 2026-08-11 | $33.16M 10-K · filed 2026-03-19 | |||||||||
| 2025-09-30 | $7.57M 10-Q · filed 2025-11-13 | $16.93M derived: sum of 2 quarters · filed 2026-08-11 | $25.71M 10-Q · filed 2025-11-13 | $32.20M derived: sum of 4 quarters · filed 2026-08-11 | |||||||||
| 2025-06-30 | $9.36M 10-Q · filed 2026-08-11 | $18.14M 10-Q · filed 2026-08-11 | $24.63M derived: sum of 3 quarters · filed 2026-08-11 | $37.92M derived: sum of 4 quarters · filed 2026-08-11 | |||||||||
| 2025-03-31 | $8.78M 10-Q · filed 2026-05-07 | $15.27M derived: sum of 2 quarters · filed 2026-05-07 | $28.56M derived: sum of 3 quarters · filed 2026-05-07 | $34.78M derived: sum of 4 quarters · filed 2026-05-07 | |||||||||
| 2024-12-31 | $6.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $19.78M derived: sum of 2 quarters · filed 2026-03-19 | $26.00M derived: sum of 3 quarters · filed 2026-03-19 | $30.79M 10-K · filed 2026-03-19 | |||||||||
| 2024-09-30 | $13.29M 10-Q · filed 2025-11-13 | $19.51M derived: sum of 2 quarters · filed 2025-11-13 | $24.30M 10-Q · filed 2025-11-13 | $28.20M derived: sum of 4 quarters · filed 2025-11-13 | |||||||||
| 2024-06-30 | $6.22M 10-Q · filed 2025-08-14 | $11.01M 10-Q · filed 2025-08-14 | $14.91M derived: sum of 3 quarters · filed 2025-08-14 | $21.14M derived: sum of 4 quarters · filed 2025-08-14 | |||||||||
| 2024-03-31 | $4.79M 10-Q · filed 2025-05-08 | $8.69M derived: sum of 2 quarters · filed 2025-05-08 | $14.91M derived: sum of 3 quarters · filed 2025-05-08 | $20.59M derived: sum of 4 quarters · filed 2025-05-08 | |||||||||
| 2023-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $10.13M derived: sum of 2 quarters · filed 2025-03-25 | $15.80M derived: sum of 3 quarters · filed 2025-03-25 | $18.64M 10-K · filed 2025-03-25 | |||||||||
| 2023-09-30 | $6.22M 10-Q · filed 2024-11-07 | $11.90M derived: sum of 2 quarters · filed 2024-11-07 | $14.73M 10-Q · filed 2024-11-07 | $15.34M derived: sum of 4 quarters · filed 2024-11-07 | |||||||||
| 2023-06-30 | $5.67M 10-Q · filed 2024-08-13 | $8.51M 10-Q · filed 2024-08-13 | $9.12M derived: sum of 3 quarters · filed 2024-08-13 | $9.77M derived: sum of 4 quarters · filed 2024-08-13 | |||||||||
| 2023-03-31 | $2.83M 10-Q · filed 2024-05-09 | $3.44M derived: sum of 2 quarters · filed 2024-05-09 | $4.09M derived: sum of 3 quarters · filed 2024-05-09 | $4.94M derived: sum of 4 quarters · filed 2024-05-09 | |||||||||
| 2022-12-31 | $606.02K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $1.26M derived: sum of 2 quarters · filed 2023-11-13 | $2.10M derived: sum of 3 quarters · filed 2023-11-13 | $3.47M 10-K · filed 2024-03-28 | $2.29M 10-K · filed 2023-03-28 | ||||||||
| 2022-09-30 | $653.00K 10-Q · filed 2023-11-13 | $491.89K 10-Q · filed 2022-11-14 | $1.50M derived: sum of 2 quarters · filed 2023-11-13 | $1.81M 10-Q · filed 2023-11-13 | $1.69M 10-Q · filed 2022-11-14 | ||||||||
| 2022-06-30 | $842.00K 10-Q · filed 2023-08-14 | $873.80K 10-Q · filed 2022-08-12 | $1.16M 10-Q · filed 2023-08-14 | $1.20M 10-Q · filed 2022-08-12 | |||||||||
| 2022-03-31 | $319.00K 10-Q · filed 2023-05-12 | $322.33K 10-Q · filed 2022-05-13 | |||||||||||
| 2021-12-31 | $720.70K 10-K · filed 2023-03-28 | ||||||||||||
| 2021-09-30 | $242.01K 10-Q · filed 2022-11-14 | $261.15K derived: sum of 2 quarters · filed 2022-11-14 | $294.19K 10-Q · filed 2022-11-14 | ||||||||||
| 2021-06-30 | $19.14K 10-Q · filed 2022-08-12 | $52.18K 10-Q · filed 2022-08-12 | |||||||||||
| 2021-03-31 | $33.04K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |